Skip to main navigation
  • FibroGen China
  • Newsroom
  • Contact
  • About Us
    • Our Company
    • Our Strategy
    • FibroGen China
    • Executive Team
    • Board of Directors
    • Our Partners
    • In Memoriam
    • Contact Us
  • Focus Areas
    • Our Expertise
    • Anemia
    • Idiopathic Pulmonary Fibrosis
    • Pancreatic Cancer
    • Duchenne Muscular Dystrophy
    • Publications
  • Pipeline
    • R&D Pipeline
    • Roxadustat
    • Pamrevlumab
  • Clinical Trials
    • Our Priorities
    • Roxadustat Trials
    • Pamrevlumab Trials
  • Careers
    • Our Culture
    • Career Opportunities
  • Investors and Media

    Investor Relations

    • Investor Overview
    • Stock Information
    • News Releases
    • Events and Presentations
    • Corporate Governance
    • SEC Filings
    • Financial Information
    • Shareholder Services
    • Investor FAQs
MENU MENU
close x
  • About Us
    • Our Company
    • Our Strategy
    • FibroGen China
    • Executive Team
    • Board of Directors
    • Our Partners
    • Contact Us
  • Focus Areas
    • Our Expertise
    • Anemia
    • Idiopathic Pulmonary Fibrosis
    • Pancreatic Cancer
    • Duchenne Muscular Dystrophy
    • Corneal Blindness
    • Publications
  • Pipeline
    • R&D Pipeline
    • Roxadustat
    • Pamrevlumab
    • FG-5200
  • Clinical Trials
    • Our Priorities
    • Roxadustat Trials
    • Pamrevlumab Trials
  • Careers
    • Our Culture
    • Career Opportunities
    • Notice to Recruiters
  • Investors and Media

    Iphone menu

    • Investor Overview
    • Stock Information
      • Stock Quote
      • Stock Chart
      • Historical Price Lookup
      • Analyst Coverage
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Documents & Charters
      • Committee Composition
      • Contact the Board
    • SEC Filings
    • Financial Information
      • Form 8937
    • Shareholder Services
      • Contact Investor Relations
      • E-mail Alerts
    • Investor FAQs
  • FibroGen China
  • Newsroom
  • Contact

Investors and Media

Committee Composition

Audit Committee Compensation Committee Nominating and Governance Committee
Suzanne Blaug Compensation Committee Nominating and Governance Committee
Aoife Brennan Compensation Committee
Benjamin Cravatt Nominating and Governance Committee
Jeffrey L. Edwards Audit Committee
Jeffrey W. Henderson Nominating and Governance Committee
Maykin Ho, PhD Audit Committee
Thomas F. Kearns, Jr. Compensation Committee
Gerald Lema Audit Committee Compensation Committee
Rory B. Riggs Compensation Committee Nominating and Governance Committee
= Chairperson = Member

Investors and Media

  • Investor Overview
  • Stock Information
  • Press Releases
  • Events & Presentations
  • Corporate Governance
    • Documents & Charters
    • Committee Composition
    • Contact the Board
  • SEC Filings
  • Financial Information
  • Shareholder Services
  • Investor FAQs

FibroGen Inc.

Volume:

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor and Media Contact

  • Investors:
    Michael Tung, M.D.
    Corporate Strategy / Investor Relations
    1.415.978.1434
    mtung@fibrogen.com

  • Media Inquiries:
    Jennifer Harrington
    +1.610.574.9196
    jennifer.harrington@gcihealth.com

Shareholder Tools

  • Print Page
  • RSS Feeds
  • E-mail Alerts

About Us

  • Our Company
  • Our Strategy
  • FibroGen China
  • Executive Team
  • Board of Directors
  • Our Partners
  • Contact Us

Focus Areas

  • Our Expertise
  • Anemia
  • Idiopathic Pulmonary Fibrosis
  • Pancreatic Cancer
  • Duchenne Muscular Dystrophy
  • Corneal Blindness
  • Publications

Pipeline

  • R&D Pipeline
  • Roxadustat
  • Pamrevlumab
  • FG-5200

Clinical Trials

  • Our Priorities
  • Roxadustat Trials
  • Pamrevlumab Trials

Careers

  • Our Culture
  • Career Opportunities
  • Notice to Recruiters

Investors & Media

Investor Relations

  • Investor Overview
  • Stock Information
  • News Releases
  • Events and Presentations
  • Corporate Governance
  • SEC Filings
  • Financial Information
  • Shareholder Services
  • Investor FAQs
  • Terms of Use
  • Privacy Policy
  • About Us
  • Focus Area
  • Pipeline
  • Clinical Trials
  • Investors and Media
  • Terms of Use
  • Privacy Notice
  • © 2021 FibroGen, Inc.
  • 409 Illinois Street, San Francisco, CA 94158